We are a clinical and commercial stage biotechnology company leading the next evolution in cellular and regenerative medicine with off-the-shelf placental-derived allogeneic cell therapies and biomaterial products designed for serious unmet medical needs.
The Next Evolution In Cellular Medicine
At Celularity, we believe that by harnessing the placenta’s unique biology, ready availability and scalability, we can develop solutions for significant unmet global needs for effective, accessible, and affordable therapeutics.
Anthrogenesis Founded
1998
Merged With Celegene
2002
Celularity Spin Out
2017
Celularity Becomes Public Company
2021
Active & Completed Trials
15+
Allogeneic Placental-Derived Cells & Biomaterials
Celularity’s innovative approach harnesses the unique therapeutic potential locked within the cells and biomaterials of the postpartum placenta. We have multiple cell therapy candidates in active clinical development as well as a broad range of placental-derived biomaterial products for therapeutic use.